Weller, Johannes http://orcid.org/0000-0001-5818-5392
Schäfer, Niklas
Schaub, Christina
Potthoff, Anna-Laura
Steinbach, Joachim P.
Schlegel, Uwe
Sabel, Michael
Hau, Peter
Seidel, Clemens
Krex, Dietmar
Goldbrunner, Roland
Pietsch, Torsten
Tzaridis, Theophilos
Zeyen, Thomas
Borger, Valeri
Güresir, Erdem
Vatter, Hartmut
Herrlinger, Ulrich
Schneider, Matthias
Funding for this research was provided by:
F. Hoffmann-La Roche
Bundesministerium für Bildung und Forschung (01KG1005)
Universitätsklinikum Bonn
Article History
Received: 1 February 2022
Accepted: 23 May 2022
First Online: 15 June 2022
Declarations
:
: UH has received lecture and/or advisory board honoraria from Medac, Noxxon, AbbVie, Bayer, Janssen, and Karyopharm. JS has received honoraria for lectures, travel or advisory board participation from Abbvie, Medac, Med-Update, Roche, Novocure and Seagen. CS has received lecture, consultation or advisory board honoraria from AbbVie, Bristol-Myers Squibb, HRA Pharma, Medac, Roche and Seagen. The other authors declare that they have no financial interests.
: Both trials were performed in line with the principles of the Declaration of Helsinki the Guidelines for Good Clinical Practice. The trials were approved by the ethics committee of all participating centers.
: Written informed consent was obtained from all individual participants included in the studies.
: All authors agreed to the publication of the manuscript.